CytomX Therapeutics reported QQ2 2024 results with meaningful topline revenue driven by collaboration activities, alongside ongoing clinical development of its PROBODY pipeline. Revenue for the quarter was $25.1 million, up modestly YoY versus Q2 2023 but down sharply QoQ from the prior quarter’s elevated level, reflecting typical quarterly variability in collaboration-driven receipts. The company posted a net loss of $6.53 million and an operating loss of $8.45 million, with a 100% gross margin on reported revenue due to recognition of collaboration-related revenue without corresponding COGS in this early-stage business model. Cash, cash equivalents and investments stood at approximately $137 million at 6/30/2024, positioning CytomX to fund operations into late-2025 absent additional milestones or new deals. Management emphasized disciplined cost control while advancing a multi-modality PROBODY program slate, including CX-904 (masked EGFR-CD3 T-cell engager), CX-2051 (EpCAM-directed PROBODY ADC), and CX-801 (masked interferon alpha 2B PROBODY cytokine). Management reiterated catalysts and data cadence through 2024–2025, including a CX-904 update by year-end 2024, initial CX-2051 data in H1 2025, and initial CX-801 data in H2 2025, with more than 10 collaborations underpinning milestone opportunities. This note evaluates how the pipeline trajectory, balance sheet dynamics, and near-term milestones shape CytomX’s risk/return profile for investors.